Effects of Cold Rolling or Precipitation Hardening Treatment on the Microstructure, Mechanical Properties, and Corrosion Resistance of Ti-Rich Metastable Medium-Entropy Alloys.

Titanium-rich metastable medium-entropy alloys, designed for low elastic moduli, sacrifice strength. However, enhancing their mechanical strength is crucial for bio-implant applications. This study aims to enhance the mechanical properties and corrosion resistance of a metastable Ti80-Nb10-Mo5-Sn5 medium-entropy alloy using various treatments, including cold rolling (at 50% and 75% reduction) and precipitation hardening (at room temperature, 150 °C, 350 °C, 550 °C, and 750 °C). The results showed that the alloy underwent a stress-induced martensitic transformation during the rolling process. Notably, the α phase was precipitated in the ß grain boundaries after 30 days of precipitation hardening at room temperature. The yield strengths of the alloy increased by 51% and 281.9% after room-temperature precipitation and 75% cold rolling, respectively. In potentiodynamic corrosion tests conducted in phosphate-buffered saline solution, the pitting potentials of the alloy treated using various conditions were higher than 1.8 V, and no pitting holes were observed on the surface of the alloys. The surface oxide layer of the alloy was primarily composed of TiO2, Nb2O5, MoO3, and SnO2, contributing to the alloy's exceptional corrosion and pitting resistance. The 75% rolled Ti80-Nb10-Mo5-Sn5 demonstrates exceptional mechanical properties and high corrosion resistance, positioning it as a promising bio-implant candidate.

A Review: Design from Beta Titanium Alloys to Medium-Entropy Alloys for Biomedical Applications.

ß-Ti alloys have long been investigated and applied in the biomedical field due to their exceptional mechanical properties, ductility, and corrosion resistance. Metastable ß-Ti alloys have garnered interest in the realm of biomaterials owing to their notably low elastic modulus. Nevertheless, the inherent correlation between a low elastic modulus and relatively reduced strength persists, even in the case of metastable ß-Ti alloys. Enhancing the strength of alloys contributes to improving their fatigue resistance, thereby preventing an implant material from failure in clinical usage. Recently, a series of biomedical high-entropy and medium-entropy alloys, composed of biocompatible elements such as Ti, Zr, Nb, Ta, and Mo, have been developed. Leveraging the contributions of the four core effects of high-entropy alloys, both biomedical high-entropy and medium-entropy alloys exhibit excellent mechanical strength, corrosion resistance, and biocompatibility, albeit accompanied by an elevated elastic modulus. To satisfy the demands of biomedical implants, researchers have sought to synthesize the strengths of high-entropy alloys and metastable ß-Ti alloys, culminating in the development of metastable high-entropy/medium-entropy alloys that manifest both high strength and a low elastic modulus. Consequently, the design principles for new-generation biomedical medium-entropy alloys and conventional metastable ß-Ti alloys can be converged. This review focuses on the design from ß-Ti alloys to the novel metastable medium-entropy alloys for biomedical applications.

Biocompatibility of a Ti-Rich Medium-Entropy Alloy with Glioblastoma Astrocytoma Cells.

Titanium and titanium alloys are widely used in medical devices and implants; thus, the biocompatibility of these metals is of great importance. In this study, glioblastoma astrocytoma cellular responses to Ti65-Zr18-Nb16-Mo1 (Ti65M, metastable medium-entropy alloy), Ti-13Nb-7Sn-4Mo (TNSM, titanium alloy), and commercially pure titanium (CP-Ti) were studied. Several physical parameters (crystal phase structure, surface roughness and hardness) of the titanium alloys were measured, and the correlation with the cellular viability was investigated. Finally, the relative protein expression in cellular proliferation pathways was measured and compared with mRNA expression assessed with quantitative real-time reverse transcription polymerase chain reaction assay (qRT-PCR).

Structure, Properties, and Corrosion Behavior of Ti-Rich TiZrNbTa Medium-Entropy Alloys with ß+α″+α' for Biomedical Application.

Five Ti-rich ß+α″+α' Ti−Zr−Nb−Ta biomedical medium-entropy alloys with excellent mechanical properties and corrosion resistance were developed by considering thermodynamic parameters and using the valence electron concentration formula. The results of this study demonstrated that the traditional valence electron concentration formula for predicting phases is not entirely applicable to medium-entropy alloys. All solution-treated samples with homogeneous compositions were obtained at a low temperature (900 °C) and within a short period (20 min). All solution-treated samples exhibited low elastic moduli ranging from 49 to 57 GPa, which were significantly lower than those of high-entropy alloys with ß phase. Solution-treated Ti65−Zr29−Nb3−Ta3 exhibited an ultra-high bending strength (1102 MPa), an elastic recovery angle (>30°), and an ultra-low elastic modulus (49 GPa), which are attributed to its α″ volume fraction as high as more than 60%. The pitting potentials of all samples were higher than 1.8 V, and their corrosion current densities were lower than 10−5 A/cm3 in artificially simulated body fluid at 37 °C. The surface oxide layers on Ti65−Zr29−Nb3−Ta3 comprised TiO2, ZrO2, Nb2O5, and Ta2O5 (as discovered through X-ray photoelectron spectroscopy) and provided the alloy with excellent corrosion and pitting resistance.

3D T1-weighted turbo spin echo contrast-enhanced MRI at 1.5 T for frameless brain metastases radiotherapy.

PURPOSE: Performance of 3D-T1W-TSE has been proven superior to 3D-MP-GRE at 3 T on brain metastases (BM) contrast-enhanced (CE) MRI. However, its performance at 1.5 T is largely unknown and sparsely reported. This study aims to assess image quality, lesion detectability and conspicuity of 1.5 T 3D-T1W-TSE on planning MRI of frameless BM radiotherapy. METHODS: 94 BM patients to be treated by frameless brain radiotherapy were scanned using 3D-T1W-TSE with immobilization on multi-vendor 1.5 T MRI-simulators. BMs were jointly diagnosed by 4 reviewers. Enhanced lesion conspicuity was quantitatively assessed by calculating contrast ratio (CR) and contrast-to-noise ratio (CNR). Signal-to-noise ratio (SNR) reduction of white matter due to the use of flexible coil was assessed. Lesion detectability and conspicuity were compared between 1.5 T planning MRI and 3 T diagnostic MRI by an oncologist and a radiologist in 10 patients. RESULTS: 497 BMs were jointly diagnosed. The CR and CNR were 75.2 ± 39.9% and 14.2 ± 8.1, respectively. SNR reduced considerably from 31.7 ± 8.3 to 21.9 ± 5.4 with the longer distance to coils. 3 T diagnostic MRI and 1.5 T planning MRI yielded exactly the same detection of 84 BMs. Qualitatively, lesion conspicuity at 1.5 T was not inferior to that at 3 T. Quantitatively, lower brain SNR and lesion CNR were found at 1.5 T, while lesion CR at 1.5 T was highly comparable to that at 3 T. CONCLUSION: 1.5 T 3D-T1W-TSE planning MRI of frameless BM radiotherapy was comprehensively assessed. Highly comparable BM detectability and conspicuity were achieved by 1.5 T planning MRI compared to 3 T diagnostic MRI. 1.5 T 3D-T1W-TSE should be valuable for frameless brain radiotherapy planning.

Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma.

BACKGROUND: Advanced inoperable hepatocellular carcinoma (HCC) conferring a grave prognosis may benefit from yttrium-90 ((90)Y) radioembolization. METHODS: Thirty patients with advanced inoperable HCC including those with any lesion >8 cm in maximal diameter or multiple bi-lobar lesions (totally more than five lesions), or portal vein thrombosis treated with radioembolization were reviewed. Treatment efficacy and safety were evaluated. Univariate and multivariate analyses were performed for identifying potential prognostic factors. RESULTS: After a median follow-up of 18.3 months, the response rate was 30.0%, and the disease control rate was 50.0%. Median overall progression-free survival (PFS) and overall survival (OS) were 3.3 months and 13.2 months, respectively. Longer median PFS was noted in those who had transarterial chemoembolization before radioembolization (7.3 months vs 3.1 months; P=0.021) and duration of alfafeto protein (AFP) response ≥6 months (11.8 months vs 3.0 months; P<0.001). Longer median OS was also revealed in those without portal vein thrombosis (17.1 months vs 4.4 months; P=0.015) and those whose duration of AFP response was ≥6 months (21.2 months vs 8.6 months; P=0.001). Seventeen patients (56.7%) developed treatment-related complications including five (16.7%) grade 3 events. Multivariate analysis revealed that treatment responders (P=0.001) and duration of AFP response ≥6 months (P=0.006) were prognostic of PFS, whereas the absence of portal vein invasion (P=0.025), treatment responders (P=0.010), and duration of AFP response ≥6 months (P=0.001) were prognostic of OS. CONCLUSION: (90)Y radioembolization is an alternative treatment with a promising outcome for poor-risk advanced inoperable HCC.

High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus.

OBJECTIVE: To investigate the prevalence of vertebral fractures and to identify risk factors associated with vertebral fractures in Chinese women with systemic lupus erythematosus (SLE). METHODS: One hundred fifty-two consecutive patients with SLE were recruited in this cross-sectional study. Bone mineral density (BMD) measurements of the hip and spine were performed using the same dual energy X-ray absorptiometry (DEXA). Lateral radiographs of the spine (T5-L4) were assessed for vertebral fractures using a method described by Genant. Inflammatory and biochemical markers included C-reactive protein, receptor activator of nuclear factor-kappaB ligand, serum ss-CrossLaps assay for C-terminal telopeptides of type 1 collagen, and osteoprotegerin (OPG). RESULTS: Asymptomatic vertebral fractures occurred in 20.4% of patients with SLE. Univariate analyses of variables associated with fractures were older age, higher body mass index (BMI), lower BMD spine, lower BMD hips, higher serum C3 and C4, longer estrogen exposure, higher levels of OPG, and the use of sunscreen. Multivariate analysis showed older age (p = 0.017), higher BMI (p < 0.036), and lower BMD of the spine were significantly associated with vertebral fractures in the thoracic and/or lumbar spine (odds ratio 1.068, 1.166, 0.005; p = 0.018, p = 0.025, p = 0.003, respectively). CONCLUSION: Asymptomatic vertebral fractures occur in 20.4% of patients with SLE and 30% of these patients have normal BMD. The current method using DEXA to predict the presence of vertebral fracture has limited value and there is a need for assessment of bone quality. Vertebral morphometry in patients with SLE is recommended and early therapeutic intervention is necessary to prevent vertebral fractures in patients with SLE.